keyword
MENU ▼
Read by QxMD icon Read
search

Nab paclitaxel

keyword
https://www.readbyqxmd.com/read/28078561/clinical-benefit-of-nanoparticle-albumin-bound-paclitaxel-in-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma-resistant-to-cremophor-based-paclitaxel-or-docetaxel
#1
Jessica Ley, Tanya M Wildes, Kristin Daly, Peter Oppelt, Douglas Adkins
The clinical benefit of nab-paclitaxel monotherapy for recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) that progressed on other taxanes (cremophor-based paclitaxel or docetaxel) is unknown. A retrospective analysis of patients treated at a single institution with nab-paclitaxel for taxane-resistant RM-HNSCC. The exploratory hypothesis was that nab-paclitaxel would result in clinical benefit (tumor response) in patients with taxane-resistant RM-HNSCC. Twelve patients who were treated with nab-paclitaxel monotherapy for taxane-resistant RM-HNSCC and met all eligibility criteria were identified...
February 2017: Medical Oncology
https://www.readbyqxmd.com/read/28069389/layer-by-layer-assembly-of-hierarchical-nanoarchitectures-to-enhance-the-systemic-performance-of-nanoparticle-albumin-bound-paclitaxel
#2
Hima Bindu Ruttala, Thiruganesh Ramasamy, Beom Soo Shin, Han-Gon Choi, Chul Soon Yong, Jong Oh Kim
Although protein-bound paclitaxel (PTX, Abraxane(®)) has been established as a standard PTX-based therapy against multiple cancers, its clinical success is limited by unfavorable pharmacokinetics, suboptimal biodistribution, and acute toxicities. In the present study, we aimed to apply the principles of a layer-by-layer (LbL) technique to improve the poor colloidal stability and pharmacokinetic pattern of nanoparticle albumin-bound paclitaxel (nab-PTX). LbL-based nab-PTX was successfully fabricated by the alternate deposition of polyarginine (pARG) and poly(ethylene glycol)-block-poly (L-aspartic acid) (PEG-b-PLD) onto an albumin conjugate...
January 6, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28061451/nanoparticle-albumin-bound-paclitaxel-as-neoadjuvant-chemotherapy-of-breast-cancer-a-systematic-review-and-meta-analysis
#3
REVIEW
Yu Zong, Jiayi Wu, Kunwei Shen
BACKGROUND: The value of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in neoadjuvant systemic therapy for breast cancer remains uncertain. METHODS: Both electronic databases and proceedings of oncologic meetings were included in systematic literature search. Pooled rates of pathological complete response (pCR), odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed-effect or random-effect model to determine the effect of neoadjuvant nab-paclitaxel...
January 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/28053544/nab-paclitaxel-as-a-potential-partner-with-checkpoint-inhibitors-in-solid-tumors
#4
REVIEW
Hatem H Soliman
Tumors recognized by the host immune system are associated with better survival. However, the immune system is often suppressed in patients with established tumor burden. Stimulating the immune system to detect and kill tumor cells has been a challenge in cancer therapy for some time. Recently, novel cancer immunotherapies, such as immune checkpoint inhibitors, monoclonal antibodies, and vaccine therapies, have emerged as promising therapeutic approaches for many solid tumors. However, for some tumors, immunotherapy alone has not provided significant benefits, and some may even be fully resistant to immunotherapy...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28050738/preoperative-neoadjuvant-chemotherapy-using-nanoparticle-albumin-bound-paclitaxel-followed-by-epirubicin-and-cyclophosphamide-for-operable-breast-cancer-a-multicenter-phase-ii-trial
#5
Manabu Futamura, Yasuko Nagao, Kazuhiro Ishihara, Makoto Takeuchi, Takumi Nakada, Yoshihiro Kawaguchi, Masayoshi Asano, Iwao Kumazawa, Takashi Shiroko, Kasumi Morimitsu, Ryutaro Mori, Masahito Nawa, Toshio Shimokawa, Kazuhiro Yoshida
BACKGROUND: Recently, the use of taxane-based regimens before anthracycline-based regimens has been shown to achieve high pathological complete response (pCR) rates in patients with breast cancer. Nanoparticle albumin-bound paclitaxel (nab-PTX) has been reported as highly effective and less toxic compared with Cremophor-based Taxol. This phase II clinical trial evaluated the safety and efficacy of preoperative neoadjuvant chemotherapy (NAC) with nab-PTX followed by an epirubicin plus cyclophosphamide (EC)-based regimen for operable breast cancer...
January 3, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28039455/a-phase-i-trial-of-azacitidine-and-nanoparticle-albumin-bound-paclitaxel-in-patients-with-advanced-or-metastatic-solid-tumors
#6
Adam L Cohen, Abhijit Ray, Matthew Van Brocklin, David M Burnett, R Chris Bowen, Donna L Dyess, Thomas W Butler, Theresa Dumlao, Hung T Khong
BACKGROUND: Secreted protein acidic and rich in cysteine (SPARC), an albumin-binding protein, is downregulated by hypermethylation in many cancers. Hypomethylating agents such as azacitidine can upregulate SPARC in tumors, which may enhance the accumulation of albumin-bound drugs at tumor site. The objectives of this phase I trial was to determine the safety and maximum tolerated dose and to assess any clinical activity of the combination of azacytidine and weekly nanoparticle-albumin-bound (nab®) paclitaxel...
December 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/28030863/real-world-clinical-practice-of-intensified-chemotherapies-for-metastatic-pancreatic-cancer-results-from-a-pan-european-questionnaire-study
#7
Nha Le, Alessio Vinci, Marvin Schober, Sebastian Krug, Muhammad A Javed, Thomas Kohlmann, Malin Sund, Albrecht Neesse, Georg Beyer
INTRODUCTION: Recently, FOLFIRINOX and gemcitabine + nab-paclitaxel have been introduced as a novel intensified chemotherapy regimen for patients with metastasized pancreatic cancer. This study aims to analyze the real-world clinical practice with FOLFIRINOX and gemcitabine + nab-paclitaxel across Europe. METHODS: Invitations to participate in an anonymous web-based questionnaire were sent via e-mail to 5,420 doctors in 19 European countries through the network of national gastroenterological, oncological, surgical and pancreatic societies as well as the European Pancreatic Club...
December 29, 2016: Digestion
https://www.readbyqxmd.com/read/28028766/health-related-quality-of-life-in-patients-with-metastatic-pancreatic-cancer
#8
Vincent Picozzi, Siva Narayanan, X Henry Hu, Jeffrey Vacirca
PURPOSE: Due to its clinical course and often-late detection, many patients with metastatic pancreatic cancer (mPC) experience poor quality of life (QoL). This pilot project assessed real-world QoL in patients with mPC at different stages of treatment. METHODS: A cross-sectional survey was conducted in the following groups of patients with mPC: before initiation of first-line (1L) chemotherapy (no treatment); with partial response (PR) or stable disease (SD) upon receipt of ≥3 cycles of 1L nab-paclitaxel plus gemcitabine (nab-paclitaxel plus gemcitabine PR or SD); and with disease progression during ≥1L chemotherapy and not currently receiving nab-paclitaxel (≥1L PD)...
December 28, 2016: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28028360/dilemma-of-first-line-regimens-in-metastatic-pancreatic-adenocarcinoma
#9
REVIEW
Marwan Ghosn, Tony Ibrahim, Tarek Assi, Elie El Rassy, Hampig Raphael Kourie, Joseph Kattan
Pancreatic cancer is one of the deadliest cancers, ranking fourth among cancer-related deaths. Despite all the major molecular advances and treatment breakthroughs, mainly targeted therapies, the cornerstone treatment of metastatic pancreatic cancer (mPC) remains cytotoxic chemotherapy. In 2016, more than 40 years after the introduction of gemcitabine in the management of mPC, the best choice for first-line treatment has not yet been fully elucidated. Two main strategies have been adopted to enhance treatment efficacy...
December 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28025779/correlation-of-ki-67-proliferative-antigen-expression-and-tumor-response-to-induction-chemotherapy-containing-cell-cycle-specific-agents-in-head-and-neck-squamous-cell-carcinoma
#10
Jonathan Chatzkel, James S Lewis, Jessica C Ley, Tanya M Wildes, Wade Thorstad, Hiram Gay, Mackenzie Daly, Ryan Jackson, Jason Rich, Randal Paniello, Brian Nussenbaum, Jingxia Liu, Barry A Siegel, Farrokh Dehdashti, Douglas Adkins
Determine if highly proliferative head and neck squamous cell carcinomas, assessed by pretreatment Ki-67 expression, respond more robustly to induction chemotherapy (IC) that is selectively toxic to cycling cells. Retrospective analysis of 59 patients treated with IC and chemoradiation. IC included either nab-paclitaxel, cisplatin, 5-FU and cetuximab (APF-C, n = 27) or docetaxel, cisplatin, 5-FU +/- cetuximab (TPF+/-C, n = 32). Ki-67 expression was assessed by immunohistochemistry. Tumor response (complete/partial/stable/progressive) at the primary site after two IC cycles was evaluated by visual examination in all patients...
December 26, 2016: Head and Neck Pathology
https://www.readbyqxmd.com/read/28011474/cervical-cancer-patient-derived-orthotopic-xenograft-pdox-is-sensitive-to-cisplatinum-and-resistant-to-nab-paclitaxel
#11
Takashi Murakami, Takuya Murata, Kei Kawaguchi, Tasuku Kiyuna, Kentaro Igarashi, Ho Kyoung Hwang, Yukihiko Hiroshima, Chihiro Hozumi, Shin Komatsu, Takashi Kikuchi, Thinzar M Lwin, Jonathan C Delong, Kentaro Miyake, Yong Zhang, Kuniya Tanaka, Michael Bouvet, Itaru Endo, Robert M Hoffman
BACKGROUND: Cervical cancer is a world-wide problem that requires transformative therapeutic strategies. We have previously developed patient-derived orthotopic xenograft (PDOX) nude-mouse models of this disease. In the present report, we demonstrate that the standard drug, cisplatinum (CDDP), is highly-effective while the new, highly-touted agent, nab-paclitaxel (NAB-PTX) is ineffective. MATERIALS AND METHODS: Cervical PDOX tumors were grown on the cervix of nude mice for 4 weeks after surgical orthotopic implantation (SOI)...
January 2017: Anticancer Research
https://www.readbyqxmd.com/read/27999204/mesothelin-targeted-immunotoxin-rg7787-has-synergistic-anti-tumor-activity-when-combined-with-taxanes
#12
Emily Kolyvas, Michael Rudloff, Marianne Poruchynsky, Rebekah Landsman, Kevin Hollevoet, David Venzon, Christine Alewine
Recombinant immunotoxins (RITs) are antibody-based therapeutics that carry a toxin payload. The RG7787 RIT targets the cancer antigen mesothelin to deliver a recombinantly-engineered, reduced immunogenicity variant of Pseudomonas exotoxin A (PE) to the cytosol where it inhibits protein synthesis. Here we demonstrate that maximal doses of RG7787 temporarily halt growth of pancreatic cancer tumor xenografts, similar to the approved drugs gemcitabine and nab-paclitaxel, however, combination of the RIT with nab-paclitaxel produces durable complete regressions in most mice...
December 16, 2016: Oncotarget
https://www.readbyqxmd.com/read/27995307/phase-i-study-of-nab-paclitaxel-plus-carboplatin-and-concurrent-thoracic-radiotherapy-in-patients-with-locally-advanced-non-small-cell-lung-cancer
#13
Kyoichi Kaira, Yoshio Tomizawa, Hisao Imai, Reiko Sakurai, Masana Matsuura, Akihiro Yoshii, Mai Ochiai, Mie Kotake, Takeshi Ebara, Jun-Ichi Saitoh, Noriaki Sunaga, Koichi Minato, Ryusei Saito, Takeshi Hisada
BACKGROUND: The aim of our study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin in combination with thoracic radiotherapy for patients with locally advanced stage III non-small cell lung cancer (NSCLC). METHODS: Weekly nab-paclitaxel plus carboplatin was administered intravenously for 6 weeks. Doses of each drug were planned as follows: level 1, 40/2; level 2, 60/2; level 3, 80/2 (nab-paclitaxel [mg/m(2)]/carboplatin [area under the plasma concentration time curve mg/ml/min])...
December 19, 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27980026/correction-sparc-expression-did-not-predict-efficacy-of-nab-paclitaxel-plus-gemcitabine-or-gemcitabine-alone-for-metastatic-pancreatic-cancer-in-an-exploratory-analysis-of-the-phase-iii-mpact-trial
#14
(no author information available yet)
No abstract text is available yet for this article.
December 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27969477/ps01-08-abound-ps2-interim-safety-results-nab-paclitaxel-carboplatin-followed-by%C3%A2-nab-paclitaxel-in-nsclc-patients-with-ecog-ps-of-2-topic-medical-oncology
#15
Ajeet Gajra, Haythem Ali, Katayoun I Amiri, Nagla A Karim, Marc R Matrana, Deborah Mulford, Teng J Ong, Alexandra Sanford, Edgardo S Santos, Mark A Socinski, David R Spigel
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27969468/mini01-20-interim-quality-of-life-qol-results-from-abound-sqm-nab-paclitaxel-carboplatin-induction-therapy-in-squamous-scc-nsclc-topic-medical-oncology
#16
Michael Thomas, Ray Page, Laurent Gressot, Davey Daniel, Daniel Morgensztern, Benjamin Levy, Maen Hussein, Mohammad Razaq, Victoria M Villaflor, Santiago P Aix, Kulumani Sivarajan, Walburga Engel-Riedel, Peter Staib, Amy Ko, Teng J Ong, Nataliya Trunova, David R Spigel
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27930644/immunotherapy-for-the-treatment-of-breast-cancer-checkpoint-blockade-cancer-vaccines-and-future-directions-in-combination-immunotherapy
#17
Heather L McArthur, David B Page
Immunotherapy encompasses both vaccines that direct immune responses to tumor-associated antigens, and checkpoint blocking antibodies that inhibit immune system suppression by targeting key pathways mediated by cytotoxic T-lymphocyte-associated antigen 4, programmed death 1 (PD-1), and programmed death ligand 1 (PD-L1). Both of these approaches currently are being explored as potential strategies for the treatment of breast cancer. Recent studies suggest that immunotherapy is poised to change the therapeutic landscape for some breast cancers...
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27920708/cutaneous-metastasis-due-to-breast-cancer-in-a-patient-with-primary-biliary-cirrhosis-a-case-report
#18
Sailaja Kamaraju, Jill Depke, Janice Povletich, Adam Currey, Elizabeth Weil
BACKGROUND: Breast cancer is the most common solid tumor to cause cutaneous metastases. These are incurable and the treatment goal is geared toward local control with surgical excision, radiation, and chemotherapy. However, treatment can be challenging in subjects with end-stage liver disease and a multidisciplinary approach is warranted. CASE REPORT: In this case report, we present a 61-year-old female with primary biliary cirrhosis and human epidermal growth factor-2 (HER-2)-positive breast cancer, who subsequently developed cutaneous metastases...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27920005/efficacy-of-nab-paclitaxel-as-second-line-chemotherapy-for-unresectable-or-recurrent-gastric-cancer
#19
Minoru Fukuchi, Erito Mochiki, Toru Ishiguro, Toshiro Ogura, Jun Sobajima, Youichi Kumagai, Keiichiro Ishibashi, Hideyuki Ishida
AIM: To evaluate the efficacy and safety of nanoparticle albumin-bound-paclitaxel (nab-PTX) as second-line chemotherapy (CT) for patients with unresectable or recurrent gastric cancer (GC). PATIENTS AND METHODS: The clinicopathological and survival data of 37 patients with unresectable or recurrent GC who underwent nab-PTX monotherapy as second-line CT, were retrospectively analyzed. RESULTS: The median number of cycles and relative dose intensity administered per patient were 5 and 90%, respectively...
2016: Anticancer Research
https://www.readbyqxmd.com/read/27919976/phase-i-study-of-triweekly-nab-paclitaxel-combined-with-s-1-in-patients-with-her2-negative-metastatic-breast-cancer
#20
Koichi Sakaguchi, Katsuhiko Nakatsukasa, Tetsuya Taguchi
AIM: We conducted a phase I study to determine the maximum tolerated dose (MTD) and recommended dose (RD) of triweekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and S-1 combination therapy in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). PATIENTS AND METHODS: This study was carried out with a 3+3 dose escalation design; patients with HER2-negative MBC received nab-paclitaxel at 180-260 mg/m(2) on day 1 and S-1 at 65-80 mg/m(2) daily on days 1-14, repeated every 3 weeks...
2016: Anticancer Research
keyword
keyword
84689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"